GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bright Green Corp (NAS:BGXX) » Definitions » EBITDA Margin %

Bright Green (Bright Green) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Bright Green EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bright Green's EBITDA for the three months ended in Mar. 2024 was $-1.73 Mil. Bright Green's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Bright Green's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Bright Green EBITDA Margin % Historical Data

The historical data trend for Bright Green's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Green EBITDA Margin % Chart

Bright Green Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - -

Bright Green Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bright Green's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Bright Green's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Green's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bright Green's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bright Green's EBITDA Margin % falls into.



Bright Green EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bright Green's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-8.253/0
= %

Bright Green's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.734/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bright Green  (NAS:BGXX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Bright Green EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bright Green's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Green (Bright Green) Business Description

Traded in Other Exchanges
N/A
Address
1033 George Hanosh Boulevard, Grants, NM, USA, 87020
Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).
Executives
Gurvinder Singh officer: Chief Executive Officer 1033 GEORGE HANOSH BOULEVARD, GRANTS NM 87020
Saleem Elmasri officer: Chief Financial Officer 450 PARK AVE SOUTH, 3RD FLOOR, NEW YORK NY 10016
Lynn Stockwell director, 10 percent owner 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Seamus Mcauley officer: Chief Executive Officer 1033 GEORGE HANOSH BOULEVARD, GRANTS NM 87020
Edward A. Robinson director, officer: Chief Executive Officer 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Alfie Morgan director 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Dean Vallore director 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Terry Rafih director, 10 percent owner 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
Robert Arnone director 401 EAST LAS OLAS BLVD., SUITE 1400, FT. LAUDERDALE FL 33301
E. Mailloux Enterprises, Inc. 10 percent owner 3129 MARENTETTE AVENUE, UNIT 2, WINDSOR A6 N8X 4G1

Bright Green (Bright Green) Headlines